| 1 |
35197546 | Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling. | 2022 Feb 23 |
5 |
| 2 |
33467441 | May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia. | 2021 Jan 15 |
1 |
| 3 |
34018029 | Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. | 2021 Jul |
1 |
| 4 |
32228672 | Inhibition of effector B cells by ibrutinib in systemic sclerosis. | 2020 Mar 30 |
1 |
| 5 |
29496671 | BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. | 2018 May 3 |
2 |
| 6 |
30123049 | Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation. | 2018 |
1 |
| 7 |
26942065 | Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. | 2016 |
1 |
| 8 |
21752263 | The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. | 2011 Jul 13 |
1 |